The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of NIH, is offering this grant to evaluate the safety and effectiveness of triple antiretroviral (ARV) drug strategies for preventing mother-to-child HIV transmission (PMTCT) in resource-constrained settings. This grant is for research comparing two key approaches: “Option B,” where ARV drugs cease post-breastfeeding for women not requiring ongoing therapy, and “Option B+,” which involves initiating lifelong ARV therapy in all pregnant women irrespective of their immune or clinical status. The goal is to provide evidence to inform global PMTCT guidelines.
Opportunity ID: 220013
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-HD-14-027 |
| Funding Opportunity Title: | Safety and Effectiveness of Triple Antiretroviral Drug Strategies for Prevention of Mother to Child HIV Transmission (R01) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health Income Security and Social Services |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.865 — Child Health and Human Development Extramural Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Feb 11, 2013 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Aug 30, 2013 |
| Current Closing Date for Applications: | Aug 30, 2013 |
| Archive Date: | Sep 30, 2013 |
| Estimated Total Program Funding: | $5,000,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Native American tribal governments (Federally recognized) City or township governments Private institutions of higher education State governments Small businesses Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) County governments Special district governments Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This funding opportunity announcement (FOA) issued by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH) invites applications to evaluate the safety and effectiveness of implementation of triple antiretroviral drug strategies for prevention of mother to child HIV transmission in resource-constrained settings – either an approach in which antiretroviral drugs stop after breastfeeding cessation in women who don’t require therapy for their own health (termed by the World Health Organization “Option B’) or a strategy in which life-long antiretroviral therapy is started in all pregnant women regardless of immune or clinical status (sometimes referred to as “Option B+”). |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-14-027.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 93.865 | ADOBE-FORMS-B2 | Adobe-Forms-B2 | PKG00164150 | Jul 30, 2013 | Aug 30, 2013 | View |
Package 1
Mandatory forms
220013 RR_SF424_1_2-1.2.pdf
220013 PerformanceSite_1_4-1.4.pdf
220013 RR_OtherProjectInfo_1_3-1.3.pdf
220013 RR_KeyPersonExpanded_1_2-1.2.pdf
220013 PHS398_CoverPageSupplement_1_4-1.4.pdf
220013 PHS398_ResearchPlan_1_3-1.3.pdf
220013 PHS398_Checklist_1_3-1.3.pdf
Optional forms
220013 RR_SubawardBudget30-1.2.pdf
220013 PHS398_ModularBudget_1_2-1.2.pdf
220013 RR_Budget-1.1.pdf
220013 PHS_CoverLetter_1_2-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
